In this phase 2 trial, researchers sought to assess whether azacitidine plus venetoclax would be superior to induction chemotherapy in certain patients with untreated AML.

Older patients with acute myeloid leukemia (AML) have a dismal prognosis, even after treatment with a hypomethylating agent. Azacitidine added to venetoclax had promising efficacy in a previous phase ...

Please provide your email address to receive an email when new articles are posted on . A 5-day azacitidine course had the most consistent survival benefit for low-risk MDS vs. other shorter ...

Please provide your email address to receive an email when new articles are posted on . Azacitidine plus venetoclax significantly improved EFS compared with induction chemotherapy for certain patients ...

Herein, we report the results of an open-label, single-center phase II clinical trial evaluating the efficacy of azacitidine in the setting of MRD-triggered (decrease of CD34 + donor chimerism below ...

- Phase 3 VIALE-A study showed a 34 percent reduction in the risk of death in AML patients who were ineligible for intensive chemotherapy treated with venetoclax plus azacitidine compared to ...

Azacitidine/Venclexta improved EFS and quality of life compared to induction chemotherapy in fit AML patients, with a 39% risk reduction in disease progression or death. The PARADIGM trial showed a ...

The Committee heard from the clinical specialists that current practice includes the use of best supportive care and, for some patients who are able to tolerate it, low- or standard-dose chemotherapy.

The chemotherapy drug azacitidine, a frontline treatment for blood cancers such as myelodysplastic syndromes and acute myeloid leukemia, kills cancer cells partly by damaging their RNA rather than ...

ORLANDO, Florida — For the first time, there is a maintenance therapy for patients with acute myeloid leukemia (AML) in remission that can improve overall survival — a new oral formulation of an old ...

Azacitidine is a pyrimidine nucleoside analog of cytidine with hypomethylating and antileukemia activity. Azacitidine has been shown to have survival benefits in patients with high-risk ...

The appraisal committee considered evidence submitted by Celgene and a review of this submission by the evidence review group (ERG). See the committee papers for full details of the evidence. The ...